cardio-symposium - lectures

Abbas, Dr. N., Kent / Canterbury, United Kingdom The relationship to renal function and left ventricular hypertrophy in chronic kidney failure

Asmar, Prof. R., Paris, France Blood pressure reduction and clinical outcomes - Update from ONTARGET

Backer De, MD G., Ghent, Belgium An Attempt to Focus the Limited Resources for Prevention in the Patients at Highest Need The POWER study

Bartnik, Dr. M., Stockholm, Sweden Impaired glucose tolerance and hidden diabetes in the cardiac patient

Bayes-Genis, Prof. A., Barcelona, Spain The use of NT-proBNP for the management of acute heart failure: diagnosis and therapy monitoring

Bell, Prof. D. S., Birmingham, United States Treatment options for diabetic heart failure - act now! Intensify!

Bhatt, Dr. D. L., Boston, United States Diabetes, platelet dysfunction and cardiovascular risk

Ceriello, Prof. A., Udine, Italy Pathophysiology of diabetes and cardiovascular disease Postprandial hyperglycaemia as a driving force in diabetes and CVD Pathophysiology: Diabetes and Cardiovascular Disease

Chiasson, Prof. J.-L., Montréal, Canada Glucose lowering interventions in diabetes and CVD - lessons from outcome studies Summary and conclusions

Christenson, Dr. R. H., Maryland, United States Clinical utility of N-terminal pro B-type natriuretic peptide in patients with heart failure and acute coronary syndrome

Cockcroft, Prof. J.R., Cardiff, United Kingdom Effects on control blood pressure and aortic pulse wave velocity. Comparison between Eprosartan and Atenolol – is it of clinical relevance?

Collinson, Dr. P. O., London, United Kingdom General and specific aspects of NTproBNP in the clinical and laboratory setting – introduction

Cosentino, Prof. F., Rome, Italy Collaborating with the diabetologist to improve management of patients with type 2 diabetes

Diehm, N., Switzerland What pre-clinical and clinical results have taught us about the PACCOCATH drug-eluting balloon coating technology

Diener, Prof. H.-C., Essen, Germany Blood pressure control: stroke and stroke prevention

Doering, Prof. W., Munich, Germany Lessons from the Schwabing Myocardial Infarction Registry

Elliott, MD H. L., Glasgow, United Kingdom Extending the blood pressure - lowering benefits of nifedipine gastrointestinal therapeutic system (GITS) to patients with isolated systolic hypertension (ISH)

Emdin, Dr. M., Pisa, Italy NT-proBNP vs. BNP for the detection of early / mild forms of heart failure Improved Early Detection of Heart Failure Patients

Filippi de, Prof. C., Maryland, United States NT-proBNP: Identifying cardiovascular disease beyond heart failure and acute coronary syndrome Diagnostic and Prognostic Value in Patients with Renal Disease

Flyvbjerg, Prof. A., Aarhus, Denmark Kidney dysfunction in diabetes - the link with cardiovascular disease

Galvani, Prof. M., Forli, Italy The use of NT-proBNP for risk stratification in coronary care unit patients

Gaziano, Dr. J. M., Boston, United States Anti-platelet therapy across the the range of CV risk Case studies

Gerstein, MD H. C., Ontario, Canada The ORIGIN trial: do omega-3 fatty acid ethyl-esters reduce cardiovascular outcomes in people with dysglycemia?

Gitt, Dr. A., Ludwigshafen, Germany Awareness: Diabetes and the Heart

Granada, J., United States What pre-clinical and clinical results have taught us about the PACCOCATH drug-eluting balloon coating technology

Halcox, Prof. J., Cardiff, United Kingdom Introduction

Haller, Prof. H., Hannover, Germany Introduction

Hanefeld, Prof. M., Dresden, Germany The endothelium as a target of high glucose attack

Hanon, MD O., Paris, France The OSCAR trial – first results

Harris, Prof. W. S., South Dakota, United States Effect of omega-3 fatty acid ethyl-esters in the treatment of dyslipidemia

Hildebrandt, Dr. P. R., Frederiksberg, Denmark Diagnosis of Heart Failure in the Outpatient Setting

Hobbs, Prof. R., Birmingham, United Kingdom Natriuretic Peptides: What are the latest studies telling us?

Holman, Prof. R., Oxford, United Kingdom Welcome & Introduction The Acarbose Cardiovascular Evaluation (ACE) study - secondary prevention of CVD in prediabetes

Hülsmann, Prof. Dr. Martin, University Hospital, Vienna, Austria Heart failure screening with NT-proBNP in primary care

Interview, Interview Dr. Plumpe/Prof. Schnell, Barcelona, Spain A New Dawn in Cardiovascular Protection

Irish, Prof. A., Perth, Australia The FAVOURED trial: background and rationale of the use of omega-3 fatty acid ethyl-esters in subjects undergoing dialysis

Januzzi, Dr. J. L., Boston, United States Diagnosis of Heart Failure in the Emergency Department International NT-proBNP consensus panel: NT-proBNP for the diagnosis of heart failure

Josse, Prof. R., Toronto, Canada Acarbose - safe and effective glycaemic control with cardiovascular benefits

Kleber, F., Germany What pre-clinical and clinical results have taught us about the PACCOCATH drug-eluting balloon coating technology

Kuck, Prof. K.-H., Hamburg, Germany Clinical Experience with Arctic Front Catheter – Single, 28mm balloon approach

Latini, MD R., Milan, Italy Improved Prognostic Value in Heart Failure Patients

Lehmkuhl, Prof. H. B., Berlin, Germany N-terminal pro brain-type natriuretic peptide as a predictor of the clinical course in patients with severe heart failure

Lewanczuk, Dr. R., Alberta, Canada Reducing the CV risk by anti-hypertensive combination strategies

Lindahl, Prof. B., Uppsala, Sweden Prognostic value of N-terminal pro brain-type natriuretic peptide in patients with unstable coronary artery disease Welcome and Introduction

Lueders, Prof. S., Cloppenburg, Germany Principal results of a prospective randomized controlled study: Morbidity and mortality after stroke – Eprosartan compared with nitrendipine for secondary prevention (MOSES) Stress-associated hypertension at the workplace – first results of the STARLET project

Maisch, Prof. B., Marburg, Germany Conclusion

Maisel, Prof. A. S., San Diego, United States B-type natriuretic peptide - a marker of heart failure in diabetes?

Mancia, Prof. G., Milano, Italy Optimal efficacy of nifedipine – a unique delivery system

Mann, Prof. J., Munich, Germany Lessons from inhibiting the renin-angiotensin-system

Mant, Prof. D., Oxford, United Kingdom Results from the medical research council observational pilot trial

Marchioli, Prof. R., Laboratory of Clinical Epidemiology, Santa Maria Imbaro, Italy The GISSI - Heart failure trial

Martinez, Prof. M., Valencia, Spain Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation and microparticle formation in hypertension. Relevant to prevent stroke?

Marx, Dr. N., Ulm, Germany Characterisation of endothelial function in the diabetic and non-diabetic heart

Mathey, D., Germany What pre-clinical and clinical results have taught us about the PACCOCATH drug-eluting balloon coating technology

McMurray, Prof. J. J. V., University of Glasgow, Glasgow, United Kingdom Successes and failures in congestive heart failure therapy

Meinertz, Prof. T., Hamburg, Germany Pitfalls of adverse events in polypharmacy for cardiac failure

Meredith, Dr. P. A., Glasgow, United Kingdom Combining antihypertensive drug classes - Extending the evidence and maximising the benefits Hypertension and the metabolic syndrome

Messerli, Prof. H., New York, United States Stroke prevention: not all antihypertensive drugs are created equal

Metra, Prof. M., Brescia, Italy Clinical value of monitoring N-terminal pro brain-type natriuretic peptide levels in patients with acute heart failure

Montserrat, Dr. J. M., Barcelona, Spain Managing SDB in high-risk asymptomatic metabolic syndrome

Moons, Prof. K. G. M., University Medical Center Utrecht, Utrecht, Netherlands Excluding venous thromboembolism in a primary care setting using a clinical decision rule and a point-of-care D-dimer assay

Müller, Prof. C., Basel, Switzerland B-Type natriuretic peptide in the evaluation and management of acute dyspnea

Nieminen, Dr. M., Helsinki, Finland ESC Guidelines for Diagnosing Chronic and Acute Heart Failure

Omland, Prof. T., Oslo, Norway Prognosis in a Broad Spectrum of Ischaemic Heart Disease

Pacher, Prof. R., Vienna, Austria The use of NT-proBNP for the management of heart failure in out-patients Clinical significance of NT-proBNP in patients with diabetes

Pan, Dr. C. Y., Beijing, China Acarbose – a safe oral anti-diabetic agent providing CV benefits

Peragallo-Dittko, V., New York, United States Translation to Practice

Pieske, Prof. B., Goettingen, Germany Pro BNP in the intensive cardiac care unit

Pitschner, PD Dr. H.-F., Bad Naunheim, Germany Arctic Front Balloon Catheter for Pulmonary Vein Isolation: Multicenter Results

Potapov, Dr. E., Berlin, Germany Natriuretic peptides as predictors of clinical course in patients with end-stage heart failure.

Price, Prof. C., London, United Kingdom The cost benefits of BNP measurement

Printzen, Dr. G., Berne, Switzerland Troponin T and D Dimer in patients with chest pain

Punjabi, Prof. N., Baltimore, United States Obstructive Sleep Apnea, Disease Definitions and Metabolic Implications

Ram, Prof. V., Dallas, United States Angiotensin Blockade with Eprosartan: Vascular and Functional Implications

Richards, Prof. A. M., Christchurch, New Zealand N-terminal pro brain-type natriuretic peptide in monitoring and guiding heart failure therapy

Roffi, PD Dr. M., Zurich, Switzerland Coronary revascularization in the diabetic patient: chosing the best treatment

Ruilope, Prof. L. M., Madrid, Spain CV risk – suggestions for a comprehensive CV risk management?

Rupp, Prof. H., Marburg, Germany Risk Reduction by Preventing Stroke. Need for Blockade of Angiotensin II and Catecholamines? Mechanisms of acion of omega-3 fatty acid ethyl esters in congestive heart failure

Rydén, Prof. L., Stockholm, Sweden Hyperglycaemia – an important risk factor in patients with cardiovascular disease Some Reflections on the Need and Implications of Joint Guidelines from the Perspective of a Cardiologist

Römer von, Dr. Wolf, Munich, Germany Welcome

Scheller, B., Germany What pre-clinical and clinical results have taught us about the PACCOCATH drug-eluting balloon coating technology

Schnell, Prof. O., München, Germany Recent guideline recommendations for managing pre- and established diabetes and CVD Oral anticoagulation in diabetes and atrial fibrillation

Schwarz, Dr. P., Dresden, Germany Education and intervention programs to prevent diabetes and its complications

Shlyakhto, Prof. E., Saint Petersburg, Russia Observational Study on Cognitive Function And SBP Reduction (OSCAR): Methodology and Appraisal

Sierra de la, Prof. A., Barcelona, Spain Welcome and Introduction Treating hypertension in the metabolic syndrome – are all drugs the same? Challenges in treating metabolic syndrome - The advantages of prescribing angiotensin receptor blockers alone and in combination

Speck, U., Germany What pre-clinical and clinical results have taught us about the PACCOCATH drug-eluting balloon coating technology

Standl, Prof. E., Munich, Germany Hyperglycemia and CV risk – recommendations from current guidelines

Szucs, Prof. Dr. Thomas, University of Zurich, Zurich, Switzerland Clinical benefit of point-of-care testing of cardiovascular biomarkers in acute coronary syndromes, heart failure and thromboembolic events in primary care

Tendera, Prof. M., Katowice, Poland Summary and closing remarks

Tepe, G., Germany What pre-clinical and clinical results have taught us about the PACCOCATH drug-eluting balloon coating technology

Tideman, Dr. P., Flinders Medical Centre, Bedford Park, Australia Impact of cardiac point-of-care in public health

Tschöpe, Prof. D., Bad Oeynhausen, Germany Glucose targets and how to achieve them in patients with dysglycaemia

Tuomilehto, Prof. J., Helsinki, Finland CV risk – an increasing global burden – how to find people at risk?

Valensi, Prof. P., Paris / Bondy, France Novel diabetes strategies and their potential to reduce the cardiovascular burden Insights from the diabetologist in improving management of patients with type 2 diabetes

Vinik, Prof. A., Norfolk, United States Cardiac denervation syndrome in diabetes and its pre-stages: Consequences for cardiac function

Von Schacky, Prof. C., Universität München, Munich, Germany Omega-3 fatty acid ethyl-esters in prevention of cardiovascular events The role of omega-3 fatty acid ethyl esters in the cardiologist´s treatment armamentarium

Wahl, Dr. H. G., Marburg, Germany Elimination of cardiac natriuretic peptides by hemodialysis

Wilding, Prof. J., Liverpool, United Kingdom Sleep Apnoea in the Diabetes Clinic

Zannad, Prof. F., Nancy, France, France Introduction: sleep disordered breathing (SDB) and co-morbidities Outcomes of appropriate treatment of SDB in co-morbidities Conclusion

Zimmet, Prof. P., Mellbourne, Australia Introduction OSA and Type 2 Diabetes: "Partners in Crime"